siRNA-mediated Erc gene silencing suppresses tumor growth in Tsc2 mutant renal carcinoma model

Cancer Letters

Volumn 268, Issue 2, 2008, Pages 278-285

  Imamura, Osamu ^a   Okada, Hiroaki ^b   Takashima, Yuuki ^b   Zhang, Danqing ^a   Kobayashi, Toshiyuki ^a   Hino, Okio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Erc gene; siRNA microspheres; Tsc2

Indexed keywords

ARGININE; LIPOSOME; MESOTHELIN; MICROSPHERE; POLYETHYLENEIMINE; POLYGLACTIN; SMALL INTERFERING RNA; TUBERIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER TRANSPLANTATION; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFICACY; ERC GENE; GENE SILENCING; IN VITRO STUDY; KIDNEY CARCINOMA; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; RAT; RNA SEQUENCE; TUMOR SUPPRESSOR GENE;

ANIMALS; CA-125 ANTIGEN; DISEASE MODELS, ANIMAL; GENE SILENCING; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICROSPHERES; RATS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS;

MUS; RATTUS;

EID: 48549107647     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.04.002     Document Type: Article

References (30)

1. Hino O., Kobayashi T., Nishizawa M., Kubo Y., Kobayashi T., Hirayama Y., Kikuchi Y., and Orimoto K. Renal carcinogenesis in the Eker rat. J. Cancer Res. Clin. Oncol. 121 (1995) 602-605
2. Hino O., Shiomi K., and Maeda M. Diagnostic biomarker of asbestos-related mesothelioma: example of translational research. Cancer Sci. 98 (2007) 1147-1151
3. Nakaishi M., Kajino K., Ikesue M., Hagiwara Y., Kuwahara M., Mitani H., Horikoshi-Sakuraba Y., Segawa T., Kon S., Maeda M., Wang T., Abe M., Yokoyama M., and Hino O. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form rat Erc/mesothelin. Cancer Sci. 98 (2007) 659-664
4. Shiomi K., Miyamoto H., Segawa T., Hagiwara Y., Ota A., Maeda M., Takahashi K., Masuda K., Sakao Y., and Hino O. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 97 (2007) 928-932
5. Shiomi K., Hagiwara Y., Sonoue K., Segawa T., Miyashita K., Maeda M., Izumi H., Masuda K., Hirabayashi M., Moroboshi T., Yoshiyama T., Ishida A., Natori Y., Inoue A., Kobayashi M., Sakao Y., Miyamoto H., Takahashi K., and Hino O. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin. Cancer Res. 14 (2008) 1431-1437
6. Maeda M., and Hino O. Blood tests for asbestos-related mesothelioma. Oncology 71 (2006) 26-31
7. Hassan R., and Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44 (2008) 46-53
8. De Fougerolles A., Manoharan M., Meyers R., and Vornlocher H.P. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymol. 392 (2005) 278-296
9. Hassani Z., Lemkine G.F., Erbacher P., Palmier K., Alfama G., Giovannangeli C., Behr J.P., and Demeneix B.A. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. 7 (2005) 198-207
10. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., and Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12 (2005) 461-466
11. Leirdal M., and Sioud M. Gene silencing in mammalian cells by preformed small RNA duplexes. Biochem. Biophys. Res. Commun. 295 (2002) 744-748
12. Sorensen D., Leirdal M., and Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327 (2003) 761-766
13. Ishii T., Ohnuma K., Murakami A., Takasawa N., Yamochi T., Iwata S., Uchiyama M., Dang N.H., Tanaka H., and Morimoto C. SS-A/Ro52, an autoantigen involved in CD28-mediated IL-2 production. J. Immunol. 170 (2003) 3653-3661
14. Ito M., Yamamoto S., Nimura K., Hiraoka K., Tamai K., and Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Med. 7 (2005) 1044-1052
15. Kim W.J., Christensen L.V., Jo S., Yockman J.W., Jeong J.H., Kim Y.H., and Kim S.W. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther. 14 (2006) 343-350
16. Zhang C., Tang N., Liu X., Liang W., Xu W., and Torchilin V.P. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control Release 112 (2006) 229-239
17. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control Release 116 (2006) 123-129
18. Grayson A.C., Doody A.M., and Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res. 23 (2006) 1868-1876
19. Werth S., Urban-Klein B., Dai L., Hobel S., Grzelinski M., Bakowsky U., Czubayko F., and Aigner A. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J. Control Release 112 (2006) 257-270
20. Matsumoto G., Kushibiki T., Kinoshita Y., Lee U., Omi Y., Kubota E., and Tabata Y. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci. 97 (2006) 313-321
21. Murata N., Takashima Y., Toyoshima K., Yamamoto M., and Okada H. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control Release 126 (2008) 246-254
22. Okada H., and Toguchi H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 1-99
23. Uehara N., Matsuoka Y., and Tsubura A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol. Cancer Res. 6 (2008) 186-193
24. Narita K., Staub J., Chien J., Meyer K., Bauer M., Friedl A., Ramakrishnan S., and Shridhar V. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res. 66 (2006) 6025-6032
25. Bridge A., and Pebernard S. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34 (2003) 263-264
26. Grimm D., Streetz K.L., Jopling C.L., Stom T.A., Pandey K., Davis C.R., Marion P., Salazar F., and Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 25 (2006) 537-541
27. Rump A., Morikawa Y., Tanaka M., Minami S., Umesaki N., Takeuchi M., and Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to Mesothelin mediates cell adhesion. J. Biol. Chem. 279 (2004) 9190-9198
28. Chang K., and Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, meotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93 (1996) 136-140
29. Gubbels J., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., Bera T.K., Connor J., Sathyanarayana B.K., Lee B., Pastan I., and Patankar M.S. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 5 (2006) 50-65
30. Frierson H., and Moskaluk C. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum. Pathol. 34 (2003) 605-609